Lee, Hwan
Scheuermann, Joshua S.
Young, Anthony J.
Doot, Robert K.
Daube-Witherspoon, Margaret E.
Schubert, Erin K.
Fillare, Matthew A.
Alexoff, David
Karp, Joel S.
Kung, Hank F.
Pryma, Daniel A.
Funding for this research was provided by:
Five Eleven Pharma Inc.
National Cancer Institute (1R44CA233140-01)
Small Business Innovation Research (1R43CA217425-01)
Article History
Received: 7 November 2021
Revised: 20 January 2022
Accepted: 8 March 2022
First Online: 29 March 2022
Declarations
:
: The University of Pennsylvania Institutional Review Board approved the study. All the procedures performed involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all the individual participants included in the study.
: David Alexoff: CEO of Five Eleven Pharma Inc.Hank F. Kung: Founder and Chairman of the board at Five Eleven Pharma Inc.Daniel A. Pryma: Research Consultant, Five Eleven Pharma Inc.; Research Consultant, Progenics Pharmaceuticals Inc.; Research Consultant, Actinium Pharmaceuticals Inc.; Research Consultant, Ipsen; Research Grant, Siemens AG; Research Grant, Five Eleven Pharma Inc.; Research Grant, Progenics Pharmaceuticals Inc.; Clinical Trial Funding, Nordic Nanovector ASA.The other authors declare that they have no conflict of interest.